Jonathan Rubin

Jonathan Rubin is the current Chief Medical Officer & SVP, Research & Development at Supernus Pharmaceuticals. Prior to this, they served as the Chief Medical Officer at Atentiv LLC from May 2018 to February 2020 and at Alcobra from August 2013 to September 2017.

At Alcobra, Jonathan was responsible for the oversight and execution of clinical and medical programs, including clinical development, medical affairs and pharmacovigilance. Jonathan successfully completed two IND applications, two phase 3 studies in adults with ADHD, including one study with electronic source, a successful phase 1 study, and a phase 2 study in Fragile X Syndrome. Additionally, they developed a novel Fragile X biomarker and helped to obtain Orphan and Fast Track designations.

Atentiv LLC is a pharmaceutical company focused on the development of new medications to help patients with cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. As Chief Medical Officer, Jonathan was responsible for clinical strategy, design of clinical trials, and assistance in Series B financing.

Jonathan Rubin has an MBA from Columbia University, and a fellowship in developmental-behavioral pediatrics from Boston Children's Hospital. Jonathan also has a residency in pediatrics from Albert Einstein/Montefiore Pediatrics Residency, and an MD from The University of Connecticut School of Medicine. Jonathan has a bachelor's degree in molecular biophysics and biochemistry from Yale University, and a certification in developmental behavioral pediatrics from the American Board of Pediatrics.

They are on a team with Padmanabh P. Bhatt - SVP, Intellectual Property and Chief Scientific Officer, Kevin T. Anderson - Compliance Officer, and Jeff Bozick - SVP, Supply Chain. Their manager is Jack A. Khattar, President & CEO.